Inmed expands patent portfolio with novel cannabinoid analogs and advances collaboration agreement with leading cannabinoid research expert

Vancouver, british columbia and south san francisco, calif., april 28, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the publication of a patent application in north america for several cannabinoid analogs. this patent application has broad claims directed to their molecular structure, uses and methods of manufacturing.
INM Ratings Summary
INM Quant Ranking